Shisi Pharmaceutical Group (02005): Fenofibrate Choline Sustained Release Capsule (135mg) obtained drug production registration approval

Zhitongcaijing · 3d ago

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The Group has obtained approval from the China National Drug Administration for the production of phenobibrate choline sustained-release capsules (135mg), which is a Class 4 chemical drug, and is deemed to have passed the consistency evaluation.

Fenofibrate choline sustained-release capsules are mainly used to reduce triglyceride levels in patients with severe hypertriglyceridemia and to treat patients with primary hypercholesterolemia or mixed dyslipidemia on the basis of a controlled diet for adults. Compared with traditional fenofibrate, fenofibrate choline has a direct effect, has a lower liver and kidney burden, is not restricted by eating, and can be safely combined with statins. It is a high-end triglyceride-lowering replacement product that is just needed clinically.